Every Form 4 that Bridgebio Pharma (BBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBIO filings page.
BridgeBio Pharma, Inc. (BBIO) reported that Chief Executive Officer and director Neil Kumar filed a Form 4 disclosing open-market sales of a total of 44,980 shares of common stock on August 18–19, 2026. Some shares were sold directly and others were sold by the Kumar Haldea Family Irrevocable Trust, where he is a co‑trustee. The transactions were effected pursuant to a Rule 10b5-1 sales plan adopted on May 13, 2026, with reported weighted average sale prices in the low-to-mid $80s per share. After these transactions, separately reported indirect holdings include 3,568,447 shares held by the Kumar Haldea Revocable Trust and 750,000 shares held by the NK 2026 GRAT, with Kumar disclaiming beneficial ownership of certain trust-held shares except to the extent of his pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) reported that President and CFO Thomas Trimarchi had 22,781 shares of common stock withheld on August 16, 2026 to satisfy tax obligations related to the vesting of 41,194 RSU-based shares. After this tax-withholding disposition, he directly held 336,529 shares, which includes 116 shares acquired on August 14, 2026 through the company’s Employee Stock Purchase Plan.
BridgeBio Pharma, Inc. (BBIO) reported that its Chief Executive Officer, Neil Kumar, had 71,217 Restricted Stock Units (RSUs) convert into an equal number of shares of common stock on August 16, 2026. Corresponding RSU derivative positions were eliminated as the awards vested and settled into common shares.
To cover associated tax obligations from this vesting, 36,237 shares of common stock were delivered or withheld at a price of $79.86 per share. Following these transactions, indirect holdings reported include 515,686 shares held by the Kumar Haldea Family Irrevocable Trust, 3,568,447 shares held by the Kumar Haldea Revocable Trust, and 750,000 shares held by the NK 2026 GRAT, with the reporting person disclaiming beneficial ownership of these trust-held shares except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) reported that Chief Accounting Officer Maricel Apuli had 4,714 shares of common stock withheld on 2026-08-16 to satisfy tax obligations related to vesting of 9,262 RSU-based shares. After this tax-withholding disposition, Apuli directly holds 122,687 shares of BridgeBio common stock.
BridgeBio Pharma Chief Accounting Officer Maricel Apuli sold 2,000 shares of Common Stock on July 30, 2026 at $80.06 per share in an open-market transaction under a Rule 10b5-1 sales plan adopted on September 8, 2025, and now directly holds 127,401 shares.
BridgeBio Pharma director Andrea Ellis reported an exercise-and-sale sequence involving 17167.0000 shares of common stock on July 9, 2026. She exercised stock options to acquire 17167.0000 shares at 16.7500 per share and sold 17167.0000 shares at 84.0000 per share in an open-market transaction pursuant to a Rule 10b5-1 sales plan adopted on December 3, 2025. The sale transaction line reports 22579.0000 common shares beneficially owned directly immediately following that sale.
BridgeBio Pharma, Inc. director Jennifer E. Cook reported an option exercise-and-sale sequence in common stock. On July 9, 2026, she exercised stock options covering 148,589 shares at exercise prices of $8.45, $16.75, and $29.00 per share, then sold 148,589 shares of common stock in open-market transactions at prices of $90.00 and $84.00 per share. The sales were effected pursuant to a Rule 10b5-1 sales plan adopted on March 16, 2026.
BridgeBio Pharma director Jennifer E. Cook reported a mix of option exercises, stock grants, and open-market sales of common stock. On June 24, 2026, she sold 37,167 shares at $70.00 and exercised options for 17,167 shares at $16.75 and 20,000 shares at $8.45 per share. Additional sales of 2,196 shares at $68.57 occurred on June 23, 2026. She also received 3,990 restricted stock units and a stock option for 5,277 shares at $68.92 on June 22, 2026. Following these transactions, she directly holds 8,383 shares of common stock. At least one sale was made under a pre-arranged Rule 10b5-1 trading plan, and the new RSUs and options generally vest in full on June 22, 2027, subject to continued board service.
BridgeBio Pharma director Hannah Valantine reported several equity transactions in the company’s stock. She sold 2,808 shares of Common Stock at $68.00 per share and 2,196 shares at $68.57 per share in open‑market sales executed under a pre‑arranged Rule 10b5‑1 sales plan adopted on November 14, 2025.
On the same date, she exercised stock options to acquire 2,808 shares at an exercise price of $41.73 per share and received a grant of 3,990 restricted stock units that will vest in full on June 22, 2027, each representing one share of Common Stock. Following these transactions, she holds 9,259 shares directly and 398 shares indirectly through her spouse.
BridgeBio Pharma director Andrew Lo reported new equity awards. He received 3,990 restricted stock units of Common Stock and now directly holds 18,079 common shares. Separately, he indirectly holds 50,583 common shares jointly with another holder.
Lo was also granted stock options for 5,277 shares of Common Stock at an exercise price of $68.92 per share, expiring on June 21, 2036. Both the RSUs and the stock options vest in full on June 22, 2027, as long as he continues serving on BridgeBio’s board of directors through that date.
BridgeBio Pharma director Charles J. Homcy reported equity awards consisting of restricted stock units and stock options. He received 3,990 RSUs, each representing a contingent right to one share of common stock, and 5,277 stock options with an exercise price of $68.92 per share.
The RSUs and the shares underlying the options vest in full on June 22, 2027, conditioned on his continued service on the board of directors through that date. Following the RSU grant, Homcy directly holds 919,876 shares of BridgeBio common stock, plus 5,277 options expiring on June 21, 2036.
BridgeBio Pharma director Eric Aguiar received new equity awards. On June 22, 2026, he was granted 3,990 restricted stock units, each representing one share of common stock, and 5,277 stock options with an exercise price of $68.92 per share.
The RSUs and the shares underlying the stock options vest in full on June 22, 2027, as long as he continues serving on the board through that date. After these awards, he holds 10,579 shares of common stock directly, plus the 5,277 options expiring on June 21, 2036.
BridgeBio Pharma director Ronald J. Daniels reported equity awards as part of his compensation. He received 3,990 restricted stock units, each representing one share of common stock, granted at no cash cost. These RSUs vest in full on June 22, 2027, if he continues serving on the board until that date.
Daniels was also granted a stock option covering 5,277 shares of common stock at an exercise price of $68.92 per share, also vesting in full on June 22, 2027, subject to continued board service. Following the RSU grant, he directly holds 20,981 shares of BridgeBio common stock. The filing shows no open‑market buys or sells, only award-related acquisitions.
BridgeBio Pharma, Inc. director Ellis Andrea reported receiving new equity awards. On June 22, 2026, Ellis was granted 3,990 restricted stock units that vest in full on June 22, 2027, subject to continued board service. Each RSU represents one share of common stock.
Ellis was also granted a stock option covering 5,277 shares of common stock at an exercise price of $68.92 per share, expiring on June 21, 2036, with all option shares vesting on June 22, 2027. Following these awards, Ellis directly holds 22,579 shares of common stock.
BridgeBio Pharma director Fred Hassan reported new equity awards in the form of stock units and options. He received 3,990 restricted stock units, each representing one future share of common stock, bringing his direct common share holdings to 29,879 after the grant.
Hassan was also granted options covering 5,277 shares of common stock at an exercise price of $68.92 per share. Both the RSUs and the option shares vest in full on June 22, 2027, conditioned on his continued service on BridgeBio’s board of directors through that date. The stock options expire on June 21, 2036.
BridgeBio Pharma director James C. Momtazee reported new equity awards and an ownership reclassification. He received 3,990 restricted stock units that each convert into one share of common stock and vest in full on June 22, 2027, if he continues serving on the board.
He was also granted a stock option for 5,277 shares of common stock at an exercise price of $68.92 per share, vesting in full on June 22, 2027. After these awards, he holds 19,070 shares directly, while 80,000 shares are now reported as indirectly owned through the James C. Momtazee Revocable Trust, which were previously reported as directly owned.
BridgeBio Pharma director Frank McCormick reported new equity awards and updated his holdings. He received 3,990 restricted stock units, each representing one share of common stock, and a stock option covering 5,277 shares at an exercise price of $68.92 per share.
The RSUs and the option shares both vest in full on June 22, 2027, conditioned on his continued service on the board. After these awards, he holds 10,579 shares directly and 756,665 shares indirectly through the Francis P. McCormick Rev Trust.
The filing also corrects a previously reported transfer of 352,290 shares that did not occur and clarifies that 428,976 shares were transferred from his direct holdings to his trust account on June 3, 2026.
BridgeBio Pharma director Douglas A. Dachille reported routine equity awards and existing indirect holdings. He received 3,990 restricted stock units (RSUs) that vest in full on June 22, 2027, contingent on his continued service on the board. Each RSU represents one share of common stock, giving him 10,579 shares of common stock held directly after the award.
He also received a stock option for 5,277 shares of common stock with a $68.92 per-share exercise price, vesting in full on June 22, 2027, also tied to continued board service. Separately, 20,000 shares of common stock are held indirectly by The Dachille 2012-1 Family Trust for his children, with his spouse as trustee. Dachille disclaims beneficial ownership of those trust shares for Section 16 and other purposes.
BridgeBio Pharma director Ali J. Satvat reported equity awards rather than market trades. He received 3,990 restricted stock units (RSUs) that vest in full on June 22, 2027, conditioned on his continued service on the board. Each RSU represents a contingent right to receive one share of BridgeBio’s common stock.
Satvat was also granted a stock option covering 5,277 shares of common stock at an exercise price of $68.9200 per share, expiring on June 21, 2036. These option shares vest in full on June 22, 2027, subject to the same continued-service condition. Following the RSU grant, he directly holds 169,983 shares of common stock.
BridgeBio Pharma director Charles J. Homcy reported a routine tax-withholding transaction related to restricted stock units. On vesting of 2,196 RSU-based common shares, 788 shares of BridgeBio Pharma, Inc. common stock were withheld at $66.27 per share to cover his tax obligations.
After this non-market disposition, Homcy directly holds 915,886 shares of BridgeBio common stock. This type of Form 4 event reflects compensation and associated taxes rather than an open-market trade expressing a view on the stock.
BridgeBio Pharma director Jennifer E. Cook reported option exercises and related share sales. On June 15, 2026, she exercised options to acquire 83,088 shares of common stock at exercise prices of $8.45 and $16.75 per share.
On the same date, she sold 90,240 shares of common stock in open-market transactions at weighted average prices of $66.6153 and $67.1425 per share, under a pre-arranged Rule 10b5-1 sales plan adopted on March 16, 2026. Following these transactions, she directly owned 8,092 shares of BridgeBio Pharma common stock.
BridgeBio Pharma, Inc. reported that family trusts associated with CEO Neil Kumar sold a total of 80,000 shares of common stock in open‑market transactions. The sales occurred on June 4 and 5, 2026 at prices generally between about $65 and $69 per share.
The transactions were executed under a pre‑arranged Rule 10b5‑1 sales plan adopted on March 31, 2025, and were made by the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, where Kumar serves as co‑trustee. He also holds 243,327 shares directly and disclaims beneficial ownership of the trust shares beyond any pecuniary interest.
BridgeBio Pharma, Inc. Chief Executive Officer and director Neil Kumar reported open-market sales of 26,103 shares of common stock on May 21, 2026. The shares were sold at weighted average prices within ranges from $66.81 to $70.97 per share under a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025.
Following these transactions, Kumar directly holds 267,174 BridgeBio common shares. In addition, the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, for which he serves as co-trustee, hold 4,358,447 and 555,686 shares, respectively, although he disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest.
BridgeBio Pharma President and CFO Thomas Trimarchi reported routine equity activity in company stock. On May 18, 2026, he made open-market sales totaling 13,651 shares of common stock at weighted average prices around the mid-$60s per share, under a pre-arranged Rule 10b5-1 sales plan. On May 16, 2026, 22,781 shares were withheld to cover taxes tied to the vesting of 41,193 RSUs, which is not an open-market sale. After these transactions, he directly holds 359,194 shares of BridgeBio common stock.
BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported routine equity compensation activity involving Restricted Stock Units (RSUs) and related tax withholding. On May 16, 2026, RSUs covering 71,215 shares of common stock vested and were converted into shares, as reflected by multiple M-code derivative exercises. A total of 36,236 shares of common stock were disposed of under code F at $66.13 per share to satisfy tax obligations, not as an open-market sale, leaving 269,430 common shares held directly. Kumar also has indirect interests in 4,358,447 common shares held by the Kumar Haldea Revocable Trust and 555,686 shares held by the Kumar Haldea Family Irrevocable Trust, with beneficial ownership of these trust holdings disclaimed except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. Chief Accounting Officer Maricel Apuli reported a share disposition tied to tax withholding on vested equity awards. On May 16, 2026, 4,714 shares of common stock were withheld at $66.13 per share to satisfy her tax obligation on the vesting of 9,260 RSU-based shares. After this withholding, she directly held 129,401 shares of BridgeBio common stock. This type of transaction is used to cover taxes on compensation-related stock vesting rather than representing an open‑market sale.
BridgeBio Pharma director Scott Randal W. exercised stock options for 10,000 shares of common stock at $16.75 per share and sold 10,000 shares in open-market transactions on May 15, 2026. The sales occurred in multiple trades at weighted average prices around the high‑$60 range under a pre-arranged Rule 10b5-1 sales plan. Following these transactions, he holds 11,589 shares directly and 4,000 shares indirectly through Thinking Bench Capital LLC.
BridgeBio Pharma, Inc. CEO Neil Kumar reported insider sales executed through family trusts. Trusts associated with him sold a total of 80,000 shares of common stock in open-market transactions on May 7–8, 2026, at weighted average prices generally between about $66 and $69 per share, under a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025. The sales were made by the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, where he serves as co-trustee and disclaims beneficial ownership beyond any pecuniary interest. After these transactions, Kumar still holds 234,451 shares of common stock directly as of May 7, 2026, in addition to substantial indirect trust holdings.
BridgeBio Pharma’s Chief Accounting Officer, Apuli Maricel, sold shares under a pre-set trading plan. On April 30, 2026, Maricel executed an open-market sale of 2,000 shares of Common Stock at $71.58 per share. After this transaction, Maricel directly holds 134,115 shares. The sale was made pursuant to a Rule 10b5-1 sales plan adopted on September 8, 2025, indicating it was pre-arranged rather than timed spontaneously.
BridgeBio Pharma, Inc. director and CEO Neil Kumar reported that entities associated with him sold a total of 80,000 shares of Common Stock of BBIO in open‑market transactions on April 9–10, 2026. The trades were executed by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he serves as co‑trustee, at prices in the mid‑$70s per share.
The filing states these sales were made under a pre‑arranged Rule 10b5‑1 sales plan adopted on March 31, 2025, and includes a disclaimer that Kumar does not admit beneficial ownership of the trust shares beyond any pecuniary interest. After the transactions, the trusts and Kumar’s direct account together still hold several million shares.
Trimarchi Thomas reported acquisition or exercise transactions in this Form 4 filing.
BridgeBio Pharma, Inc. reported that its President and CFO, Thomas Trimarchi, received a grant of 59,041 restricted stock units (RSUs) of common stock as equity compensation. Each RSU represents a right to receive one share of common stock. The RSUs vest as to 1/16 of the underlying shares on May 16, 2026, and 1/16 each quarter thereafter, conditioned on his continued service. Following this grant, Trimarchi directly holds 395,626 shares of BridgeBio common stock.
BridgeBio Pharma, Inc. reported that Chief Accounting Officer Maricel Apuli received a grant of 14,170 restricted stock units (RSUs) of common stock as equity compensation. The award was made at no cash cost to Apuli and increases her direct holdings to 136,115 shares.
The RSUs vest over time, with 1/16 of the units scheduled to vest on May 16, 2026, and 1/16 vesting each quarter thereafter until fully vested, contingent on her continued service with BridgeBio or its subsidiaries. Each RSU converts into one share of common stock upon vesting, providing long-term, service-based incentive alignment.
BridgeBio Pharma, Inc. reported that Chief Executive Officer Neil Kumar received new equity awards on March 17, 2026. He was granted stock options for 40,570 shares of common stock at an exercise price of $70.94 per share, expiring on March 16, 2036.
He also received 104,313 restricted stock units (RSUs), each representing one share of common stock. Both the option and RSU awards vest in equal 1/16 installments beginning on May 16, 2026, then quarterly, as long as he continues serving the company or its subsidiaries.
BridgeBio Pharma CEO Neil Kumar reported insider sales executed by family trusts holding company stock. On March 12–13, 2026, trusts for which he is co‑trustee sold a total of 80,000 shares of BridgeBio common stock in open‑market transactions at prices around the high‑$60s to about $70.18 per share.
After these sales, one family irrevocable trust held 635,686 shares, a revocable trust held 4,438,447 shares, and Kumar also reported 234,451 shares held directly. The transactions were carried out under a pre‑arranged Rule 10b5‑1 sales plan, and Kumar disclaimed beneficial ownership of the trust‑held shares except to the extent of any pecuniary interest.
BridgeBio Pharma director Hannah Valantine exercised stock options to acquire 8,671 shares of common stock at $27.36 per share on March 10, 2026. She then sold the same 8,671 shares at $72.00 per share in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she holds 7,465 shares directly and 398 shares indirectly through her spouse.
BridgeBio Pharma, Inc. director Andrea Ellis exercised stock options and sold shares in a pre‑planned trade. On March 4, 2026, Ellis exercised options for 64,921 shares of common stock at $8.45 per share, converting a previously held stock option that had vested in three annual installments beginning on June 22, 2023 and ending on June 22, 2025. The same day, Ellis sold 64,921 shares of common stock at a weighted average price of $64.8681 per share, within a range of $64.255 to $65.21, under a Rule 10b5‑1 sales plan adopted on December 3, 2025, and held 18,589 shares directly afterward.
BridgeBio Pharma director Hannah Valantine exercised stock options for 25,484 shares on February 27, 2026, converting a “Stock Option (Right to Buy)” into common stock at an exercise price of $0.00 per share, with the resulting common shares reported at $48.45 per share.
On the same date, she sold 14,584 common shares at a weighted average price of $67.0793 and 10,900 shares at $67.8437 in open-market transactions executed under a Rule 10b5‑1 sales plan adopted on November 14, 2025. After these trades, she held 7,465 common shares directly and 398 shares indirectly through her spouse.
BridgeBio Pharma’s Chief Accounting Officer, Maricel Apuli, reported an open-market sale of 2,000 shares of common stock on February 26, 2026 at $66 per share. The transaction was executed under a pre-arranged Rule 10b5-1 sales plan adopted on September 8, 2025. Following this sale, Apuli directly holds 121,945 BridgeBio shares.
BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported open-market sales of a total of 28,053 shares of common stock on February 19, 2026. The sales were executed in three tranches of 18,923, 8,528 and 602 shares at weighted average prices of $71.0347, $72.0804 and $72.8010 per share, respectively, pursuant to a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025.
Following these transactions, Kumar directly owned 234,451 shares of BridgeBio common stock. He also had indirect ownership of 675,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,478,447 shares through the Kumar Haldea Revocable Trust, as co-trustee, while disclaiming beneficial ownership except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. director and CEO Neil Kumar reported equity compensation-related transactions involving restricted stock units (RSUs) and common stock on February 16, 2026. He acquired multiple blocks of common stock at $0.00 per share through the exercise or conversion of RSUs, which each represent a contingent right to receive one share of common stock.
To cover tax obligations triggered by the vesting of 64,698 RSU-based shares, 30,970 shares of common stock were disposed of at $75.25 per share via share withholding, rather than an open-market sale. Following these transactions, he continued to hold a significant number of shares directly, and additional common stock is held indirectly through the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he is a co-trustee. He disclaims beneficial ownership of the trust-held shares except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. Chief Accounting Officer Maricel Apuli reported two transactions in the company’s common stock. On February 17, 2026, Apuli executed an open-market sale of 510 shares at $74.31 per share under a pre-arranged Rule 10b5-1 trading plan. On February 16, 2026, 4,349 shares were withheld to cover taxes tied to the vesting of 8,377 restricted stock units. After these transactions, Apuli directly owned 123,945 shares, which include the 510 shares acquired on February 13, 2026 through the company’s employee stock purchase plan.
BridgeBio Pharma President and CFO Thomas Trimarchi reported a mix of tax withholding and planned share sales. On February 16, 2026, he disposed of 18,819 shares of common stock at $75.25 per share to cover taxes tied to the vesting of 37,503 RSU-based shares. On February 17, 2026, he sold a total of 13,600 shares of common stock in open-market transactions at prices of $74.7068 and $75.38 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 336,585 shares of BridgeBio common stock.
BridgeBio Pharma director Scott Randal W. reported a mix of option exercises and share sales. On February 17, 2026, he exercised stock options for 10,000 shares of Common Stock at $16.75 per share and acquired the underlying shares.
That same day, he sold a total of 10,000 Common Stock shares in open-market transactions at weighted average prices within ranges of $73.74–$76.23 per share, pursuant to a Rule 10b5-1 sales plan adopted on June 27, 2025. After these transactions, he holds 14,896 shares directly and 4,000 shares indirectly through Thinking Bench Capital LLC.
BridgeBio Pharma’s Chief Executive Officer, Kumar Neil, reported indirect open-market sales of the company’s common stock on February 10–11, 2026. The transactions were executed by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he serves as co-trustee, under a Rule 10b5-1 sales plan adopted on March 31, 2025. Individual trades included, for example, 14,201 shares sold at a weighted average price of $71.8018 per share and 7,806 shares at $70.6887 per share. After these sales, the trusts continued to hold large indirect positions, including 675,686 and 4,478,447 shares, and the Form 4 notes that the reporting person disclaims beneficial ownership beyond any pecuniary interest.
BridgeBio Pharma, Inc. insider activity centers on trusts associated with its Chief Executive Officer. A Form 4 reports that on January 8 and 9, 2026, the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, for which the CEO is a co‑trustee, sold multiple blocks of BridgeBio common stock under a Rule 10b5‑1 sales plan adopted on March 31, 2025.
The reported weighted average sale prices for these transactions range from about $73.05 to $78.32 per share, with examples including 11,515 shares at a weighted average price of $73.6446 and 10,519 shares at $77.6086. Following the reported trades, the family irrevocable trust held 715,686 shares, the revocable trust held 4,518,447 shares, and 228,776 shares were held directly. The reporting person disclaims beneficial ownership of the trust‑held shares except to the extent of any pecuniary interest.
BridgeBio Pharma's chief executive officer and director reported multiple stock transactions in December 2025. On December 12, 2025, 60,975 restricted stock units converted into common stock, and 30,964 shares were withheld to satisfy tax obligations linked to this vesting.
On December 15, 2025, the officer sold 28,311 shares at a weighted average price of $74.5997 and 1,700 shares at $75.2412 under a Rule 10b5-1 sales plan adopted on March 31, 2025. After these transactions, the officer directly owned 228,776 shares, with an additional 755,686 and 4,558,447 shares held indirectly through family trusts, subject to a disclaimer of beneficial ownership beyond any pecuniary interest.
BridgeBio Pharma, Inc. reported an insider equity transaction by its President and CFO. On 12/12/2025, 13,826 shares of the company’s common stock were withheld at $75.15 per share to cover the executive’s tax obligations related to equity compensation.
The tax withholding was connected to the vesting of 25,000 shares of common stock underlying the executive’s restricted stock units. Following this transaction, the reporting officer directly beneficially owns 369,004 shares of BridgeBio Pharma common stock.
BridgeBio Pharma, Inc. reported an equity transaction by its Chief Accounting Officer, Maricel Apuli. On 12/12/2025, 2,003 shares of common stock were withheld to satisfy the officer's tax obligation arising from the vesting of 3,944 restricted stock units. The transaction price reported for the withheld shares was $75.15 per share. After this withholding, the officer beneficially owned 128,294 shares of BridgeBio Pharma common stock in direct ownership.
BridgeBio Pharma, Inc. (BBIO) Chief Executive Officer and director Kumar Haldea reported open-market sales of the company’s common stock on 11/20/2025 under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025. He sold 6,401 shares at a weighted average price of $64.9706, 14,299 shares at a weighted average price of $65.904, and 5,456 shares at a weighted average price of $66.7129, with each price reflecting sales across specified ranges. Following these transactions, Haldea directly held 228,776 shares and also had indirect beneficial ownership of 795,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares through the Kumar Haldea Revocable Trust, where he serves as co-trustee and disclaims beneficial ownership except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) director insider transactions were reported on a Form 4. A reporting person serving as a director disclosed open-market sales of BridgeBio common stock on 11/17/2025 and 11/18/2025 at weighted average prices ranging from about $64.58 to $67.20 per share, with specific weighted averages of $66.6263, $67.056, $65.2315, and $66.049 for the reported trades.
Following these transactions, the director beneficially owned 14,089 shares of common stock directly and 50,583 shares indirectly through joint tenancy with Nancy N. Lo. The price ranges for each trade are available, and the reporting person has undertaken to provide detailed breakdowns of the individual sale prices within each range upon request.